ZyVersa is committed to improving health outcomes and quality of life for patients with inflammatory and renal diseases.
ZyVersa Therapeutics has raised $2.0M in total funding. The most recent round was Post-IPO Equity. The last funding was announced in March 2025.
ZyVersa Therapeutics's investors include Michael J. Fox Foundation.
ZyVersa Therapeutics is headquartered in Weston, United States.
ZyVersa is committed to improving health outcomes and quality of life for patients with inflammatory and renal diseases.
ZyVersa Therapeutics is at the Post-IPO Equity stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"ZyVersa Therapeutics — Funding & Investors." VCBacked, March 6, 2025, https://www.vcbacked.co/company/zyversa-therapeutics. Accessed August 16, 2026.
VCBacked. (2025). ZyVersa Therapeutics — Funding & Investors. Retrieved August 16, 2026, from https://www.vcbacked.co/company/zyversa-therapeutics
{{cite web |title=ZyVersa Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/zyversa-therapeutics |website=VCBacked |access-date=August 16, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated